Monkeypox stocks rose in after-hours trading, with Virax Biolabs up 2.98%, Emergent BioSolutions gaining 0.96% and SIGA Technologies rising 0.33%.

Monkeypox stocks fell in after-hours trading, with Valeant Pharmaceuticals International down 1.1%, Inovio Pharmaceuticals falling 0.7% and Sigma-Aldopa Corp sliding 2.5%.

Monkeypox stocks fell in regular trading, with Moderna down 2.5%, Gilead Sciences falling 2.9% and SigA sliding 2.6%.

SIGA Technologies reported a 65% drop in profits due to a decline in revenue, yet still managed to turn a profit, pay a special dividend, and complete a major government contract. The company sold $37 million in TPOXX, marking the last procurement order under the 19C contract. Despite the challenging comparison, SIGA's ability to generate revenue and remain profitable suggests potential for continued growth.

SIGA Technologies

SIGA Tech Posts 65% Profit Drop, Pays Special Dividend

SIGA Technologies relies heavily on its single antiviral product, Tpoxx, which is used to treat the smallpox virus. Tpoxx has received FDA approval and is also stockpiled by the US government. SIGA has a relatively stable revenue stream from government contracts and potential sales. The company's main risk is its dependence on Tpoxx sales, but it also has opportunities for growth through potential future government contracts and potential sales in other countries.

SIGA News